TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors. TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.
The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138. These results are important because they suggest that TTX-MC138 may be safely administered at doses that produce measurable drug exposure, a critical step in the development of any new cancer therapy. The absence of dose-limiting toxicities clears a major hurdle for advancing the candidate into later-stage trials, while the early signs of disease stabilization provide a preliminary signal of clinical activity that warrants further investigation.
TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. By focusing on this specific molecular profile, TransCode aims to address a patient population with high unmet need. The Phase 1a data therefore not only validate the safety profile of the company’s lead candidate but also support the broader RNA therapeutic approach for high-risk cancers. For a clinical-stage company like TransCode, positive early-stage results can be pivotal for attracting further investment and partnership interest, as they de-risk the program and provide a foundation for designing larger efficacy trials.
To view the full press release, visit https://ibn.fm/g3E2F. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides services including editorial syndication to 5,000+ outlets and social media distribution to help companies reach a wide audience. For full terms of use and disclaimers, see https://www.InvestorWire.com/Disclaimer.
